Company: SCLXW
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0000950170-25-006774
Chunk: 92

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 424B3
Chunk 92
---
 |     |      | (92,926 | ) |     |         |  26,579 |   |
| Income tax expense                                     |     |                                 |       — |   |     |      |       5 |   |     |         |      (5 | ) |
| Net loss                                               |     | $                               | (66,347 | ) |     | $    | (92,931 | ) |     | $       |  26,584 |   |

Comparison of the Nine Months Ended September 30, 2024 and 2023

Net Revenue

Net revenue for the nine months ended September 30, 2024 and 2023 was $41.7 million and $33.3 million, respectively. The increase of$8.4 millionwas driven by the increase in gross product sales of ZTlido and ELYXYB by approximately 12% and 110%, respectively, driven by the increase in the sales volume and a standard industry annual price increase, andsales of GLOPERBA commencing in June 2024, partiallyoffset by an increase in rebates.

Cost of Revenue

<div align='center'>49</div>

Cost of revenue for the nine months ended September 30, 2024 and 2023 was $12.0 million and $11.2 million, respectively. The increase of $0.8 million was primarily due to an increase in gross revenue of approximately 16%, partially offset by a decrease in logistics costs due to no air shipments used during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023.

Research and Development Expenses

The following table summarizes research and development expenses by project for the nine months ended September 30, 2024 and 2023 (in thousands):

| SP-102                                  |     | Nine Months Ended September 30, 
 2024                            |       |   |     | 2023 |        |     | Increase   
 (Decrease) |        |   |
|:----------------------------------------|:----|:--------------------------------|------:|:--|:----|:-----|-------:|:----|:-----------|-------:|:--|
| Contracted R&D                          |     | $                               | 1,032 |   |     | $    |  1,230 |     | $          |   (198 | ) |
| Personnel                               |     |                                 |